medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 1

<< Back Next >>

Ann Hepatol 2013; 12 (1)

Patients younger than forty years old with hepatitis C virus genotype-1 chronic infection had treatment responses similar to genotype-2 infection and not related to interleukin-28B polymorphism

Chun-Yen L, I-Shyan S, Wen-Juei J, Chang-Wen H, Chien-Hao H, Ji-Yih C

Language: English
References: 32
Page: 62-69
PDF size: 117.30 Kb.


ABSTRACT

Background and rationale. Age is one of the predictors for sustained virological response (SVR) when treating chronic hepatitis C (CHC) patients with pegylated-interferon/ribavirin (PegIFN/RBV). However, the treatment responses of the young patients had not been analyzed before. Therefore, we conducted this study to investigate the treatment responses of CHC patients younger than 40 years old (y/o). Material and methods. We retrospectively analyzed our prospective cohort of genotype 1 (GT1)- and genotype 2 (GT2)-CHC patients who received 24-week PegIFN/RBV treatment. We divided these patients into two groups according to their age younger or older than 40 y/o. Clinical parameters including viral responses and single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) had been analyzed. Results. In GT1- CHC patients, the rapid, complete early viral response rates and the SVR rate were significantly higher in patients younger than 40 y/o. In GT-1 CHC patients younger than 40 y/o, the SVR rate was similar to the GT2-CHC patients, either with high or low baseline viral load. As for the SVR predictors, in CHC patients younger than 40 y/o, only BMI but not the genotype of HCV, not baseline viral load, and not IL28B SNP was the predictor. Conclusions. GT1-CHC patients younger than 40 y/o had SVR rate similar to GT2-CHC patients. The IL28B polymorphism had no impact on the SVR rate in these young GT1-CHC patients.


REFERENCES

  1. Marc GG, Doris BS, David LT, Leonard BS. Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 2009; 49: 1335-74.

  2. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 2009; 24: 336-45.

  3. Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005; 352: 2609-17.

  4. Sanaa MK, Samer SEK, Michelle DS, Mohamed H, Imad NA, Mohamed M, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response. Hepatology 2007; 46: 1732-40.

  5. Yu ML, Dai CY, Huang JF, Chiu CF, Yang YH, Hou NJ, et al. Rapid virological response and treatment duration forchronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-93.

  6. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006; 44: 97-103.

  7. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135: 451-8.

  8. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS, et al. Pegylated interferon-alpha-2a plus ribavirin for treatmentnaive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-9.

  9. Moreno C, Deltenre P, Pawlotsky J-M, Henrion J, Adler M, Mathurin P. Shortened treatment duration in treatmentnaive genotype 1 HCV patients with rapid virological response: A meta-analysis. J Hepatol 2010; 52: 25-31.

  10. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  11. Mangia A, Minerva N, Bacca D, Cozzolongo R, Ricci GL, Carretta V, et al. Individualized treatment duration for hepatitis C genotype 1 patients: A randomized controlled trial. Hepatology 2008; 47: 43-50.

  12. Shiffman ML, Suter F, Bacon BR, Nelson D, Harley H, Sola R, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007; 357: 124-34.

  13. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment- induced viral clearance. Nature 2009; 461: 399-401.

  14. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O/’hUigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.

  15. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-[alpha] and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 41: 1105-9.

  16. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-4.

  17. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y, et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatol 2006; 44(Sup.1): S19-S24.

  18. Huang C-F, Yang J-F, Dai C-Y, Huang J-F, Hou N-J, Hsieh M-Y, et al. Efficacy and Safety of Pegylated Interferon Combined with Ribavirin for the Treatment of Older Patients with Chronic Hepatitis C. J Infectious Diseases 2010; 201: 751-9.

  19. Kainuma M, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Tanabe Y, et al. Pegylated interferon alpha-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol 2010; 16: 4400-9.

  20. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon £2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. The Lancet 1998; 352: 1426-32.

  21. Bedossa P. Intraobserver and Interobserver Variations in Liver Biopsy Interpretation in Patients with Chronic Hepatitis C. Hepatology 1994; 20: 15-20.

  22. Chen JY, Lin CY, Wang CM, Lin YT, Kuo SN, Shiu CF, et al. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-[alpha] plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun 2011; 12: 300-9.

  23. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.

  24. Afdhal NH, McHutchison JG, Zeuzem S, Mangia A, Pawlotsky JM, Murray JS, et al. Hepatitis C pharmacogenetics: State of the art in 2010. Hepatology 2011; 53: 336-45.

  25. O’Rahilly S, Spivey RS, Holman RR, Nugent Z, Clark A, Turner RC. Type II diabetes of early onset: a distinct clinical and genetic syndrome? Br Med J (Clin Res Ed) 1987; 294: 923-8.

  26. Lyssenko V, Almgren P, Anevski D, Orho-Melander M, Sjögren M, Saloranta C, et al. Genetic Prediction of Future Type 2 Diabetes. PLoS Med 2005; 2: e345.

  27. Ooi BS, Chen BT, Toh CC, Khoo OT. Causes of hypertension in the young. Br Med J 1970; 3: 744-6.

  28. Garrison RJ, Kannel WB, Stokes J, Castelli WP. Incidence and precursors of hypertension in young adults: The Framingham offspring study. Preventive Medicine 1987; 16: 235-51.

  29. Chen C-H, Chang T-T, Cheng K-S, Su W-W, Yang S-S, Lin HH, et al. Do young hepatocellular carcinoma patients have worse prognosis? The paradox of age as a prognostic factor in the survival of hepatocellular carcinoma patients. Liver International 2006; 26: 766-73.

  30. Lam CM, Chan AOO, Ho P, Ng IOL, Lo CM, Liu CL, et al. Different presentation of hepatitis B-related hepatocellular carcinoma in a cohort of 1863 young and old patientsimplications for screening. Alimentary Pharmacology & Therapeutics 2004; 19: 771-7.

  31. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for Untreated Chronic HCV Genotype 1 Infection. N Engl J Med 2011; 364: 1195-206.

  32. Lin CY, Chen JY, Lin TN, Jeng WJ, Huang CH, Huang CW, et al. IL28B SNP rs12979860 is a critical predictor for ontreatment and sustained virologic response in patient with hepatitis C virus genotype-1 infection. PLoS ONE. 2011.




2020     |     www.medigraphic.com